STRATA Skin Sciences Announces Publication Of Clinical Study On TheraClearX For Treating Mild-To-Moderate Acne In June 2024 Issue Of Journal Of Clinical And Aesthetic Dermatology
Portfolio Pulse from Benzinga Newsdesk
STRATA Skin Sciences announced the publication of a clinical study on TheraClearX for treating mild-to-moderate acne in the June 2024 issue of the Journal of Clinical and Aesthetic Dermatology.
June 07, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
STRATA Skin Sciences announced the publication of a clinical study on TheraClearX for treating mild-to-moderate acne, which could boost investor confidence and potentially increase stock prices.
The publication of a clinical study in a reputable journal can enhance the credibility of TheraClearX, potentially leading to increased sales and investor confidence, which may positively impact the stock price of STRATA Skin Sciences.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100